S
Satsuma Pharmaceuticals
Developing best-in-class products to address the unmet needs of migraine sufferers
About Satsuma Pharmaceuticals
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine sufferers. The company operates primarily in the healthcare and pharmaceutical sectors, targeting individuals who experience acute migraine attacks. Satsuma's flagship product, STS101, is a novel investigational drug-device combination designed for intranasal administration of dihydroergotamine mesylate (DHE). This product aims to provide a reliable and effective treatment option for migraines, especially for patients whose conditions are nonresponsive to existing therapies like triptans.
Satsuma's business model revolves around the research, development, and eventual commercialization of STS101. The company generates revenue through clinical trials, partnerships, and potential future sales of its proprietary drug. By leveraging advanced nasal drug delivery systems and engineered drug particle technologies, Satsuma aims to offer a differentiated therapeutic option that could significantly reduce healthcare costs associated with migraine-related productivity losses.
The company serves a niche market of migraine sufferers, estimated to contribute to $36 billion annually in lost productivity in the U.S. alone. With operations based in South San Francisco, CA, and Research Triangle Park, NC, Satsuma is well-positioned to advance its clinical trials and bring STS101 to market upon regulatory approval.
Source: Dealroom company dataAt a glance
- Founded
- 2016
- Headquarters
- San Francisco, United States
- Sector
- Biotech & Life Sciences
News
Open roles
Satsuma Pharmaceuticals in the San Francisco ecosystem
The Satsuma Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
TPG
RA Capital Management
TPG Biotech
Wellington Management
Eventide Asset Management
Lumira Ventures
Shin Nippon Biomedical Laboratories (SNBL)
SBI Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Satsuma Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Satsuma Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

